Health states/outcomes evaluation is an integral part of medical economics. Generic utility instruments compare quality of life (QoL) effects of healthcare interventions across a wide spectrum of diseases and patient populations. This study seeks to determine whether these generic instruments are sensitive to ocular diseases, where expected QoL effects of treatment are patient comfort and symptoms relief, rather than additional quality-adjusted life years (QALYs).
Methods:
Targeted search and systematic review of refereed studies on dry eye therapy with omega-3 fatty acids (omega-3s) were performed across four databases to identify clinical effectiveness parameters and outcomes. An alternative utility instrument for measuring comparative vision/opthalmic-related QoL effects of pharmaceutical-grade fish oils is used for illustration.
Results:
Most studies utilise common parametric indices of omega-3 therapy in dry eye. VisQoL appears sufficiently sensitive and customisable to a QoL impact assessment of omega-3s. Clinical outcomes and covariates can be matched to VisQoL in capturing aspects of vision functioning that are vital for patient daily performance and well-being, U = x / n. In contrast, generic measures tend to be content-insensitive to changes in vision/opthalmic-related QoL.
Conclusions:
Relevance, reliability and validity of multi-attribute utility measures in ocular conditions, like dry eye, can be assessed in terms of four key factors addressed by VisQoL: (a) sensitivity to ocular condition; (b) correlation with clinical parametric data; (c) customisability based on presenting symptoms; and (d) suitability to comparative investigations of intervention effectiveness relative to vision-related QoL.
AlexanderL. J. (2011). Is there a difference between re-esterified triglyceride and ethyl ester fish oil? A scientific and economic assessment. Advanced Ocular Care, 2(January/February), 20–21.
BhargavaR., ChandraM., BansalU., SinghD., RanjanS., & SharmaS (2016). A randomized controlled trial of omega 3 fatty acids in Rosacea patients with dry eye symptoms. Current Eye Research, 41(10), 1274–1280.
4.
BhargavaR., & KumarP. (2015). Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea, 34(4), 413–420.
5.
BhargavaR., KumarP., & AroraY. (2016). Short-term omega 3 fatty acids treatment for dry eye in young and middle-aged visual display terminal users. Eye and Contact Lens, 42(4), 231–236.
6.
BhargavaR., KumarP., KumarM., MehraN., & MishraA. (2013). A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. International Journal of Ophthalmology, 6(6), 811–816.
7.
BhargavaR., KumarP., PhogatH., KaurA., & KumarM. (2015). Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye. Contact Lens & Anterior Eye: The Journal of the British Contact Lens Association, 38(3), 206–210.
8.
BhargavaR., RajpootM., AroraY., SharmaS. K., & SharmaS. (2017). Dietary omega-3 fatty acids supplements for dry eye in psoriasis: Are they Effective?Journal of Clinical and Diagnostic Research, 11(11), NC01–NC05.
9.
BleichrodtH., & QuigginJ. (1999). Life-cycle preferences over consumption and health: When is cost-effectiveness analysis equivalent to cost–benefit analysis? Journal of Health Economics, 18(6), 681–708.
10.
BorderK. C. (1992). Revealed preference, stochastic dominance and the expected utility hypothesis. Journal of Economic Theory, 56, 20–42.
11.
BrazierJ., UsherwoodT., HarperR., & ThomasK. (1998). Deriving a preference-based single index from the UK SF-36 Health Survey. Journal of Clinical Epidemiology, 51(11), 1115–1128.
12.
ChinneryH. R., GolborneC. N., & DownieL. E. (2017). Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: A pilot study. Ophthalmic & Physiological Optics: The Journal of the British College of Ophthalmic Opticians, 37(4), 473–481.
13.
CunninghamD.N., & WhitleyW.O. (2016). The how and why of diagnosing dry eye. Review of Optometry, 153(3), 75–80.
DevriesD., JohnstonJ., KislanT., & WhitleyW. (2017, June 21–25). Innovations in MGD: Raising the standard of care [Paper presentation]. 2017 Optometry’s Meeting, Washington D.C.
16.
DeinemaL. A., VingrysA. J., WongC. Y., JacksonD. C., ChinneryH. R., & DownieL. E. (2017). A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology, 124(1), 43–52.
17.
DrummondM., SculpherM., TorranceG., O’BrienB., & StoddartG. (2005). Methods for the economic evaluation of health care programmes (3rd ed). Oxford University Press.
18.
EpitropoulosA. T., DonnenfeldE. D., ShahZ. A., HollandE. J., GrossM., FaulknerW. J., MatossianC., LaneS. S., ToyosM.Jr, BucciF. A., & PerryH. D. (2016). Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea, 35(9), 1185–1191.
19.
EuroQoL Group. (1990). EuroQoL: A new facility for the measurement of health-related QoL. Health Policy, 16(3), 199–208.
20.
EuroQoL Research Foundation. (2018). EQ-5D-3L user guide, 2018: Basic information on how to use the EQ-5D-3L instrument. https://euroqol.org/publications/user-guides/(accessed January 11, 2020).
21.
FaulknerW. J. (2017). The role of omega-3 essential fatty acids in dry eye disease. International Journal of Clinical and Experimental Ophthalmology, 1(1), 055–059.
22.
FeenyD., FurlongW., TorranceG. W., GoldsmithC. H., ZhuZ., DePauwS., DentonM., & BoyleM. (2002). Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.
23.
FiscellaR. G. (2011). Understanding dry eye disease: A managed care perspective. American Journal of Managed Care, 17(16), S432–439.
24.
GeorgakopoulosC. D., MakriO. E., PagoulatosD., VasilakisP., PeristeropoulouP., KouliV., EliopoulouM. I., & PsachouliaC. (2017). Effect of omega-3 fatty acids dietary supplementation on ocular surface and tear film in diabetic patients with dry eye. Journal of the American College of Nutrition, 36(1), 38–43.
25.
GothwalV. K., & BaggaD. K. (2013). Utility values in the visually impaired: Comparing time-trade off and VisQoL. Optometry and Vision Science, 90(8), 843–854.
26.
GoyalP., JainA. K., & MalhotraC. (2017). Oral omega-3 fatty acid supplementation for laser in situ keratomileusis-associated dry eye. Cornea, 36(2), 169–175.
27.
GNC Live Well. (n.d.) GNC Triple strength fish oil. https://www.gnc.com/best-sellers-shop-all/735337.html?
28.
GrassiaT., HollandE. J., & MaskinS. L. (2011). Clearer understanding of precursors of meibomian gland dysfunction warranted. Ocular Surgery News, 29(3), 21.
29.
HomM. M., AsbellP., & BarryB. (2015). Omegas and dry eye: More knowledge, more questions. Optometry and Vision Science, 92(9), 948–956.
KleijnenS., Alves T.L., MeijboomK., LipskaI., De BoerA., LeufkensH. G., & GoettschW. G. (2017). The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. Quality of Life Research, 26(9), 2479–2488.
34.
KorbD. R., BlackieC. A., FinnemoreV. M., & DouglassT. (2015). Effect of using a combination of lid wipes, eye drops, and omega-3 supplements on meibomian gland functionality in patients with lipid deficient/evaporative dry eye. Cornea, 34(4), 407–412.
35.
LempM. A., CrewsL. A., BronA. J., FoulksG. N., & SullivanB. D. (2012). Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea, 31(5), 472–478.
36.
LipnerM. (2008). Dry eye patterns with lissamine green. Eye world digital. https://www.eyeworld.org/article-dry-eye-patterns-with-lissamine-green(accessed June 28, 2020).
37.
LempM.A. (2007). The definition and classification of dry eye: Report of the definition and classification subcommittee of the international dry eye workshop (DEWS). The Ocular Surface, 5(2), 75–91.
38.
MacsaiM. S. (2008). The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (An AOS thesis). Transactions of the American Ophthalmological Society, 106(2008), 336–356.
39.
MalhotraC., SinghS., ChakmaP., & JainA. K. (2015). Effect of oral omega-3 fatty acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: A prospective placebo-controlled study. Cornea, 34(6), 637–643.
40.
MendozaR. L. (2018). Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. Journal of Medical Economics, 21(8), 733–744.
41.
MiljanovićB., TrivediK. A., DanaM. R., GilbardJ. P., BuringJ. E., & SchaumbergD. A. (2005). Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. American Journal of Clinical Nutrition, 82(4), 887–893.
42.
MisajonR. (2020, July 5). Interview. Melbourne, Australia.
43.
MisajonR., HawthorneG., RichardsonJ., BartonJ., PeacockS., IezziA., & KeeffeJ. (2005). Vision and QoL: The development of a utility measure. Investigative Ophthalmology & Visual Science, 46(11), 4007–4015.
44.
MohammadpourM., MehrabiS., HassanpoorN., & MirshahiR. (2017). Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial. Journal of Current Opthalmology, 29(1), 33–38.
45.
MisajonR., HawthorneG., RichardsonJ., BartonJ., PeacockS., IezziA., & KeeffeJ. (2005). Vision and quality of life: The development of a utility measure. Investigative Ophthalmology & Visual Science, 46(11), 4007–4015.
46.
NicholsK. K., Foulks. G.N., BronA. J., GlasgowB. J., DogruM., TsubotaK., LempM. A., & SullivanD. A. (2011). The international workshop on meibomian gland dysfunction: Executive summary. Investigative Ophthalmology & Visual Science, 52(4), 1922–1929.
47.
O’DellL. E. (2015, January 12). Using the SPEED questionnaire to identify dry eye (p. 1). Optometry Times. https://www.optometrytimes.com/view/using-speed-questionnaire-identify-dry-eye
48.
OleñikA., Jiménez-AlfaroI., Alejandre-AlbaN., & Mahillo-FernándezI. (2013). A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clinical Interventions in Aging, 8(2013), 1133–1138.
49.
OlsenN. (2020, January 20). What are the best sources of omega-3? Medical News Today. https://www.medicalnewstoday.com/articles/323144(accessed February 26, 2020).
50.
OlsenJ. A., & MisajonR. (2020). A conceptual map of health-related quality of life dimensions: Key lessons for a new instrument. Quality of Life Research, 29(3), 733–743.
51.
OngN. H., PurcellT. L., Roch-LevecqA. C., WangD., IsidroM. A., BottosK. M., HeichelC. W., & SchanzlinD. J. (2013). Epithelial healing and visual outcomes of patients using omega-3 oral nutritional supplements before and after photorefractive keratectomy: A pilot study. Cornea, 32(6), 761–765.
52.
PeacockS., MisajonR., IezziA., RichardsonJ., HawthorneG., & KeeffeJ. (2008). Vision and QoL: Development of methods for the VisQoL vision-related utility instrument. Ophthalmic Epidemiology, 15(4), 218–223.
PRNewswire Research and Markets (2020). Global omega-3 market set to reach $8.5 billion by 2025. https://www.prnewswire.com/news-releases/global-omega-3-market-set-to-reach-8-5-billion-by-2025—marine-source-of-omega-3-is-the-highly-preferred-source-for-infant-nutrition-300980829.html
55.
RamaaC. S., ShirodeA. R., MundadaA. S., & KadamV. J. (2006). Nutraceuticals—an emerging era in the treatment and prevention of cardiovascular diseases. Current Pharmaceutical Biotechnology, 7(1), 15–23.
56.
RichardsonJ., IezziA., PeacockS., SinhaK., KhanM. A., MisajonR., & KeeffeJ. (2012). Utility weights for the vision-related assessment of quality of life (AQoL)-7D instrument. Ophthalmic Epidemiology, 19(3), 172–182.
57.
RichardsonJ., IezziA., SinhaK., KhanM. A., PeacockS., HawthorneG., MisajonR., & KeeffeJ. (2009). AQoL-7D (Vision) instrument: Overview, survey results and utility algorithms. Centre for Health Economics, Monash University.
58.
OphthalmologyShort Hills (2017). Fish oil triglycerides vs. ethyl esters. https://shorthillseye.com/fish-oil-triglycerides-vs-ethyl-esters/(accessed June 1, 2020).
59.
SinghM., PapasA., & GilbardJ. P. (2008). The effect of an omega-3 supplement on dry mouth and dry Eye in Sjögren's patients. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology, 106(3): e7.
60.
SintonenH. (2001). The 15D instrument of health-related quality of life: Properties and applications. Annals of Medicine, 33(5), 328–336.
61.
SummertonS. (2015). Omega-3s: What they can do for you. Review of Optometry, 152(7), 32–38.
62.
TolleyK. (2009). What are health utilities? Hayward Medical Communications. http://www.bandolier.org.uk/painres/download/What%20is%202009/What_are_health_util.pdf
